Clinical Scorecard: IRIS Registry Analysis Shows Vision Gains With Aflibercept 8 mg
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |
| Key Mechanisms | Aflibercept 8 mg (Eylea HD) improves visual acuity and extends injection intervals. |
| Target Population | Treatment-naïve and treatment-experienced patients with wet AMD and DME. |
| Care Setting | Ophthalmology clinics utilizing real-world data from the IRIS registry. |
Key Highlights
- Treatment-naïve patients achieved 12-week injection intervals after 6 months.
- Vision gain of 4 letters in AMD and 5 letters in DME for treatment-naïve patients.
- Treatment-experienced patients maintained vision and extended injection intervals by 2 weeks.
Guideline-Based Recommendations
Diagnosis
- Utilize visual acuity assessments and imaging for diagnosis of wet AMD and DME.
Management
- Consider switching from aflibercept 2 mg to 8 mg for treatment-experienced patients.
Monitoring & Follow-up
- Regularly monitor visual acuity and injection intervals.
Risks
- Monitor for potential adverse effects associated with aflibercept treatment.
Patient & Prescribing Data
Patients with wet AMD and DME, both treatment-naïve and treatment-experienced.
Aflibercept 8 mg shows improved outcomes in visual acuity and injection frequency.
Clinical Best Practices
- Follow evidence-based protocols for monitoring and managing AMD and DME.
- Educate patients on the importance of adherence to treatment schedules.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
